Armistice Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Armistice Capital’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$52.7M	Sell	15,028,000 -997,000	-6%	-$4.09M	0.94%	16
2025 Q4	$54M	Sell	16,025,000 -125,000	-0.8%	-$325K	0.64%	23
2025 Q3	$21.2M	Hold	16,150,000	–	–	0.31%	49
2025 Q2	$11.6M	Buy	16,150,000 +2,450,000	+18%	+$1.92M	0.2%	64
2025 Q1	$20.1M	Buy	13,700,000 +4,232,000	+45%	+$10.1M	0.3%	62
2024 Q4	$41.9M	Buy	9,468,000 +1,268,000	+15%	+$5.14M	0.57%	33
2024 Q3	$33.8M	Buy	8,200,000 +400,000	+5%	+$2.15M	0.54%	34
2024 Q2	$50.9M	Buy	7,800,000 +2,400,000	+44%	+$17M	0.64%	23
2024 Q1	$47M	Sell	5,400,000 -300,000	-5%	-$3.64M	0.62%	23
2023 Q4	$65.2M	Buy	5,700,000 +2,244,000	+65%	+$22.2M	0.89%	19
2023 Q3	$33.3M	Buy	+3,456,000	New	+$33.9M	0.51%	38

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Armistice Capital's IRWD Position: Q1 2026 in Review

Armistice Capital reduced its Ironwood Pharmaceuticals (IRWD) stake by 6.2% in Q1 2026, selling an estimated $4.09M and leaving 15,028,000 shares worth $52.7M. The position accounts for 0.94% of the portfolio, ranked #16.

Armistice Capital first reported a position in IRWD in Q3 2023 and has held it in 11 quarters since. The position peaked at $65.2M in Q4 2023. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

Armistice Capital held 15,028,000 shares of Ironwood Pharmaceuticals worth $52.7M as of Q1 2026.
Armistice Capital sold 997,000 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $4.09M.
Ironwood Pharmaceuticals made up 0.94% of Armistice Capital's portfolio in Q1 2026, its #16 holding.
Armistice Capital first reported a position in Ironwood Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Armistice Capital's Ironwood Pharmaceuticals position peaked at $65.2M in Q4 2023.
226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.